11 results on '"Rymuza, Bartosz"'
Search Results
2. Impact of previous coronary artery revascularization on outcomes in patients undergoing transcatheter aortic valve implantation.
- Author
-
Wilimski, Radosław, Huczek, Zenon, Krauz, Kamil, Rymuza, Bartosz, Mazurek, Maciej, Scisło, Piotr, Zbroński, Karol, Grodecki, Kajetan, Kochman, Janusz, and Kuśmierczyk, Mariusz
- Subjects
HEART valve prosthesis implantation ,CORONARY artery bypass ,CORONARY arteries ,PERCUTANEOUS coronary intervention ,CORONARY artery disease ,ACUTE kidney failure - Abstract
Introduction: Coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis (AS) referred for transcatheter aortic valve implantation (TAVI) raises questions regarding the safety and efficacy of TAVI in this subset of patients. Aim: To evaluate the impact of previous coronary revascularization in terms of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) on clinical outcomes after TAVI. Material and methods: A total of 507 consecutive patients who underwent TAVI were divided into: non-revascularization (NR), post-PCI and post-CABG groups. The endpoints were established according to VARC-2 definitions. Results: Patients with previous coronary revascularization (36.7% of the population) were younger, more often male and their EuroSCORE II risk evaluation was significantly higher (NR 7.9% vs. post-PCI 8.0% vs. post-CABG 20.5%, p < 0.0001). Patients after PCI or CABG prior to TAVI had similar 30-day all-cause mortality rates as those without coronary revascularization at baseline (NR vs. post-PCI vs. post-CABG: 8.1% vs. 5.5% vs. 6.8%, respectively; p = 0.6). There were no differences in 12-month all-cause mortality rates between groups (NR vs. post-PCI vs. post-CABG: 15.3% vs. 14.2% vs. 16.9%, respectively; log-rank p = 0.67). In the Cox proportional-hazards regression model, acute kidney injury stage 2-3 (HR = 3.7, 95% CI: 2.14-6.33; p < 0.001) and post-TAVI stroke (HR = 3.5, 95% CI: 1.57-7.8; p = 0.002) were independently correlated with 1-year mortality. Conclusions: TAVI seems to be a safe and effective procedure for the treatment of severe AS in patients with previous coronary revascularization. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Long-term mortality after transcatheter aortic valve implantation for aortic stenosis in immunosuppressiontreated patients: a propensity-matched multicentre retrospective registry-based analysis.
- Author
-
Walczewski, Michał, Gąsecka, Aleksandra, Witkowski, Adam, Dabrowski, Maciej, Huczek, Zenon, Wilimski, Radosław, Ochała, Andrzej, Parma, Radosław, Rymuza, Bartosz, Grygier, Marek, Jemielity, Marek, Olasińska-Wiśniewska, Anna, Jagielak, Dariusz, Targoński, Radosław, Pastuszak, Krzysztof, Grešner, Peter, Grabowski, Marcin, and Kochman, Janusz
- Subjects
HEART valve prosthesis implantation ,AORTIC stenosis ,RETROSPECTIVE studies - Abstract
Introduction: Data regarding patients with a previous medical record of immunosuppression treatment who have undergone transcatheter aortic valve implantation (TAVI) are limited and extremely inconclusive. Available studies are mostly short term observations; thus there is a lack of evidence on efficacy and safety of TAVI in this specific group of patients. Aim: To compare the in-hospital and long-term outcomes between patients with or without a medical history of immunosuppressive treatment undergoing TAVI for aortic valve stenosis (AS). Material and methods: We conducted a retrospective registry-based analysis including patients undergoing TAVI for AS at 5 centres between January 2009 and August 2017. The primary endpoint was long-term all-cause mortality. Secondary endpoints comprised major vascular complications, life-threatening or disabling bleeding, stroke and new pacemaker implantation. Results: Of 1451 consecutive patients who underwent TAVI, two propensity-matched groups including 25 patients with a history of immunosuppression and 75 patients without it were analysed. No differences between groups in all-cause mortality were found in a median follow-up time of 2.7 years following TAVI (p = 0.465; HR = 0.73; 95% CI: 0.30-1.77). The rate of major vascular complications (4.0% vs. 5.3%) was similar in the two groups (p = 1.000). There were no statistically significant differences in the composite endpoint combining life-threatening or disabling bleeding, major vascular complications, stroke and new pacemaker implantation (40.0% vs. 20.0%, p = 0.218). Conclusions: Patients who had undergone TAVI for AS had similar long-term mortality regardless of whether they had a previous medical record of immunosuppression. Procedural complication rates were comparable between the groups. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Ten-year experience with transcatheter aortic valve implantation in bicuspid aortic valve: lessons learned and future perspectives.
- Author
-
Walczewski, Michał, Gasecka, Aleksandra, Huczek, Zenon, Rymuza, Bartosz, and Kochman, Janusz
- Subjects
HEART valve prosthesis implantation ,MITRAL valve ,AORTIC valve ,TRICUSPID valve surgery ,AORTIC stenosis ,TRICUSPID valve - Abstract
Bicuspid aortic valve (BAV) stenosis has traditionally been perceived as a contraindication to transcatheter aortic valve implantation (TAVI) due to its specific anatomical characteristics including extensive calcifications, high leaflet coaptation and frequently encountered aortic root dilation, which may result in worse procedural outcomes and higher risk of complications. Hence, BAV patients were not included in previous clinical trials. In the recent years, improved pre-procedural imaging and technological advances have gradually enabled expansion of TAVI to patients with complex anatomy, including those with BAV. Moreover, indications for TAVI are expanding to a younger group of patients with fewer comorbidities, and BAV is more prevalent in this population. Contemporary multicenter registry-based studies indicate that patients undergoing TAVI for BAV have similar outcomes as those with tricuspid aortic valve stenosis. In this article, we provide a thorough overview of the available clinical data regarding the outcomes of TAVI in BAV, from the perspective of an experienced TAVI center with over 150 TAVIs in this group of patients, performed in our institution since the year 2009. We present anatomical and clinical classifications of BAV, differences in outcomes in patients with bicuspid and tricuspid valves, as well as important topics regarding choice of an adequate valve and valve size. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Non-calcific aortic tissue quantified from computed tomography angiography improves diagnosis and prognostication of patients referred for transcatheter aortic valve implantation.
- Author
-
Grodecki, Kajetan, Tamarappoo, Balaji K, Huczek, Zenon, Jedrzejczyk, Szymon, Cadet, Sebastien, Kwiecinski, Jacek, Rymuza, Bartosz, Parma, Radoslaw, Olasinska-Wisniewska, Anna, Fijalkowska, Jadwiga, Protasiewicz, Marcin, Walczak, Andrzej, Nowak, Adrianna, Gocol, Radoslaw, Slomka, Piotr J, Reczuch, Krzysztof, Jagielak, Dariusz, Grygier, Marek, Wojakowski, Wojciech, and Filipiak, Krzysztof J
- Subjects
BLOOD vessels ,HEART valve prosthesis implantation ,CONFIDENCE intervals ,STROKE ,MULTIVARIATE analysis ,AORTIC stenosis ,CARDIOVASCULAR diseases ,CALCINOSIS ,COMPUTED tomography ,ODDS ratio ,AORTIC valve - Abstract
Aims We aimed to investigate the role of aortic valve tissue composition from quantitative cardiac computed tomography angiography (CTA) in patients with severe aortic stenosis (AS) for the differentiation of disease subtypes and prognostication after transcatheter aortic valve implantation (TAVI). Methods and results Our study included 447 consecutive AS patients from six high-volume centres reporting to a prospective nationwide registry of TAVI procedures (POL-TAVI), who underwent cardiac CTA before TAVI, and 224 matched controls with normal aortic valves. Components of aortic valve tissue were identified using semi-automated software as calcific and non-calcific. Volumes of each tissue component and composition [(tissue component volume/total tissue volume) × 100%] were quantified. Relationship of aortic valve composition with clinical outcomes post-TAVI was evaluated using Valve Academic Research Consortium (VARC)-2 definitions. High-gradient (HG) AS patients had significantly higher aortic tissue volume compared to low-flow low-gradient (LFLG)-AS (1672.7 vs. 1395.3 mm
3 , P < 0.001) as well as controls (509.9 mm3 , P < 0.001), but increased non-calcific tissue was observed in LFLG compared to HG patients (1063.6 vs. 860.2 mm3 , P < 0.001). Predictive value of aortic valve calcium score [area under the curve (AUC) 0.989, 95% confidence interval (CI): 0.981–0.996] for severe AS was improved after addition of non-calcific tissue volume (AUC 0.995, 95% CI: 0.991–0.999, P = 0.011). In the multivariable analysis of clinical and quantitative computed tomography parameters of aortic valve tissue, non-calcific tissue volume [odds ratio (OR) 5.2, 95% CI 1.8–15.4, P = 0.003] and history of stroke (OR 2.6, 95% CI 1.1–6.5, P = 0.037) were independent predictors of 30-day major adverse cardiovascular event (MACE). Conclusion Quantitative CTA assessment of aortic valve tissue volume and composition can improve detection of severe AS, differentiation between HG and LFLG-AS in patients referred for TAVI as well as prediction of 30-day MACEs post-TAVI, over the current clinical standard. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
6. Use of protamine sulfate during transfemoral transcatheter aortic valve implantation -- a preliminary assessment of administration rate and impact on complications.
- Author
-
Zbroński, Karol, Grodecki, Kajetan, Gozdowska, Roksana, Jędrzejczyk, Szymon, Ostrowska, Ewa, Wysińska, Julia, Rymuza, Bartosz, Scisło, Piotr, Wilimski, Radosław, Kochman, Janusz, Filipiak, Krzysztof J., Opolski, Grzegorz, and Huczek, Zenon
- Subjects
PROTAMINES ,HEART valve prosthesis implantation - Abstract
Introduction: Bleeding complications after transcatheter aortic valve implantation (TAVI) are an important issue and negatively affect survival. The rate and impact of protamine sulfate (PS) administration on bleeding complications after TAVI remain unclear. Aim: To assess the impact of PS on bleeding complications after TAVI. Material and methods: Between March 2010 and November 2016 two hundred fifty-eight patients qualified for TAVI in one academic center were screened. Baseline, procedural and follow-up data up to 30 days were collected and analyzed. The primary endpoint (PE) was major bleeding according to the Valve Academic Research Consortium up to 48 h after the procedure. Results: Overall, 186 patients (96 females, mean age: 80 years) met the inclusion criteria. Thirty-nine (21%) subjects received PS. PE occurred in 24.7% of the study population. There were no significant differences in terms of the PE rate between the groups (25.6% in the PS group and 24.7% in the remaining cohort, p = 0.9, odds ratio (OR) = 1.05, confidence interval (CI): 0.47--2.4, p = 0.9). Multivariate analysis identified female gender (OR = 2.2, CI: 1.08--4.4, p = 0.03) as an independent predictor of PE occurrence. Similarly, female gender (OR = 2, CI: 1.06--3.84, p = 0.03) as well as general anesthesia (GA, OR = 2.23, CI: 1.13--4.63, p = 0.02) and dose of unfractionated heparin per kilogram (UFH/kg, OR = 1.02, CI: 1--1.03 per 1 IU increment, p = 0.02) predicted the occurrence of a composite of major and minor bleeding. Conclusions: In this analysis, PS administration did not decrease the PE rate. Female gender predicted PE occurrence. Randomized, placebo-controlled trials are required to accurately assess the impact of PS. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Transcatheter aortic valve implantation in patients with bicuspid aortic valve stenosis utilizing the next-generation fully retrievable and repositionable valve system: mid-term results from a prospective multicentre registry.
- Author
-
Kochman, Janusz, Zbroński, Karol, Kołtowski, Łukasz, Parma, Radosław, Ochała, Andrzej, Huczek, Zenon, Rymuza, Bartosz, Wilimski, Radosław, Dąbrowski, Maciej, Witkowski, Adam, Scisło, Piotr, Grygier, Marek, Lesiak, Maciej, and Opolski, Grzegorz
- Abstract
Background: The aim of this study was to evaluate the outcomes of transcatheter aortic valve implantation (TAVI) in bicuspid aortic valve (BiAV) stenosis using a mechanically expanded Lotus™ device. The prior experience with first-generation devices showed disappointing results mainly due to increased prevalence of aortic regurgitation (AR) that exceeded those observed in tricuspid stenosis. Methods and results: We collected baseline, in-hospital, 30-day and 2-year follow-up data from a prospective, multicentre registry of patients with BiAV undergoing TAVI using Lotus™ valve. Safety and efficacy endpoints were assessed according to VARC-2 criteria. The study group comprised 24 patients. The mean age was 73.5 years and the mean EuroSCORE 2 was 4.35 ± 2.56%. MDCT analysis revealed Type 1 BiAV in 75% of patients. The mean gradient decreased from 60.1 ± 18.3 to 15 ± 6.4 mm Hg, the AVA increased from 0.6 ± 0.19 to 1.7 ± 0.21 cm
2 . One in-hospital death was observed secondary to aortic perforation. There was no severe AR and the rate of moderate AR equalled 9% at 30 days (n = 2). Device success was achieved in 83% and the 30-day safety endpoint was 17%. In the 2-year follow-up, the overall mortality was 12.5% and the 2-year composite clinical efficacy endpoint was met in 25% of the patients (n = 6) Conclusions: The TAVI in selected BiAV patients using the Lotus™ is feasible and characterized by encouraging valve performance and mid-term clinical outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
8. Different types of endocarditis after transcatheter aortic valve implantation.
- Author
-
Scisło, Piotr, Grodecki, Kajetan, Rymuza, Bartosz, Kochman, Janusz, Opolski, Grzegorz, Huczek, Zenon, and Wilimski, Radosław
- Subjects
ENDOCARDITIS ,AORTIC stenosis ,DIAGNOSTIC imaging ,ECHOCARDIOGRAPHY ,PROSTHETIC heart valves ,SURGICAL complications ,TREATMENT effectiveness ,RETROSPECTIVE studies - Abstract
Introduction: Infective endocarditis (IE) may take different faces in patients after transcatheter aortic valve implantation (TAVI). Objectives: The primary aim of this study was to describe echocardiographic and clinical characteristics of TAVI's patients suffered from IE. Methods: In a single‐center, retrospective study we analyzed 311 consecutive patients treated with TAVI for severe aortic stenosis between 2010 and 2018. Results: According to modified Duke criteria, we confirmed IE in 2.2% of the cohort, however PVE of TAVI's valve in 1.2% only; rest of the group suffered from CDRiE and IE of the mitral valve. In PVE's group vegetations were localized inside the frame with or without bioprosthesis moderate stenosis or regurgitation. Only 1 pts developed significant TAVI's bioprosthesis' paravalvular leak. We observed no native aortic anulus involvement. Mortality rate in the PVE‐TAVI's group was 75% regardless of the type of treatment. Conclusions: The above findings show that IE following TAVI is a serious complication and various scenarios (also CDRiE and native valve IE) should be considered. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. Paradoxical low-flow aortic stenosis -- baseline characteristics, impact on mortality.
- Author
-
Zbroński, Karol, Huczek, Zenon, Gawalko, Monika, Ćwiek, Agata, Rymuza, Bartosz, Grodecki, Kajetan, Scisło, Piotr, Wilimski, Radosław, Kochman, Janusz, Filipiak, Krzysztof J., and Opolski, Grzegorz
- Subjects
AORTIC stenosis ,AORTIC valve ,MORTALITY ,PERCUTANEOUS balloon valvuloplasty ,KIDNEY failure ,MULTIVARIATE analysis - Abstract
Introduction: Paradoxical low-flow, low-gradient aortic stenosis (pLF-LGAS) constitutes an important part of the population undergoing transcatheter aortic valve implantation (TAVI). However, it remains the least defined subtype of aortic stenosis (AS). Aim: To investigate baseline characteristics and impact on mortality of pLF-LGAS in patients treated with TAVI. Material and methods: Two-hundred and thirty-one consecutive patients (mean aortic valve area: 0.76 ±0.41 cm2) who underwent TAVI in our centre during the period of 6 years were included in the study. Based on echocardiographic examination, patients with pLF-LGAS were identified, analysed and compared to a population with high-gradient AS (HGAS) and low-flow, low-gradient AS with reduced ejection fraction (classical, cLF-LGAS). The primary endpoints of the study were all-cause mortality after 30 days and 1 year. Results: pLF-LGAS was diagnosed in 42 (18.2%) patients, whereas 40 (17.3%) had cLF-LGAS and 149 (64.5%) had HGAS. The pLF-LGAS population was younger, had higher prevalence of hypertension, and had higher ejection fraction (EF) than the HGAS population, and had a smaller proportion of heavily symptomatic patients than the cLF-LGAS population. Overall, 46 (19.9%) patients died within 12 months after TAVI. The 30-day and 1-year survival was comparable between AS subtypes. Multivariate analysis identified severe renal failure as an independent predictor of mortality among all patients. Conclusions: pLF-LGAS is common among subjects undergoing TAVI. Patients with paradoxical AS are younger, more often burdened with hypertension and have higher EF than the HGAS population, while being less symptomatic than the cLF-LGAS group. Presence of pLF-LGAS does not seem to affect short- and mid-term survival. Severe renal failure is an independent predictor of mortality after TAVI. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Left ventricular remodelling pattern and its relation to clinical outcomes in patients with severe aortic stenosis treated with transcatheter aortic valve implantation.
- Author
-
Rymuza, Bartosz, Zbroński, Karol, Scisło, Piotr, Wilimski, Radosław, Kochman, Janusz, Ćwiek, Agata, Filipiak, Krzysztof J., Opolski, Grzegorz, and Huczek, Zenon
- Subjects
- *
LEFT ventricular hypertrophy , *CHEMOEMBOLIZATION , *CARDIAC hypertrophy , *HEMODYNAMICS , *HEART failure - Abstract
Introduction: Left ventricular hypertrophy (LVH) is a common compensating process in the pressure overload mechanism of aortic stenosis (AS). Aim: To identify a group of patients with a LVH pattern which may alter periprocedural and 1-year outcomes after transcatheter aortic valve implantation (TAVI). Material and methods: Echocardiographic examinations of 226 patients with severe AS treated with TAVI between March 2010 and February 2016 were retrospectively analysed and correlated with echocardiographic parameters and clinical outcomes in the study group. Ultimately 208 patients were enrolled in the study. Based on left ventricular mass index (LVMI) and relative wall thickness (RWT) patients were divided into three categories: concentric remodelling (CR), concentric hypertrophy (CH) and eccentric hypertrophy (EH). Most of the patients with severe AS referred for TAVI were found to have CH (n = 150, 72.8%), then EH (n = 33, 16%) and CR (n = 16, 7.8%). Results: There were no significant differences between groups in terms of periprocedural outcomes or complications. After a mean observation time of 561.8 ±239.0 days, the observed all-cause mortality rate was 19.9%. After multivariable adjustment, CR remained associated with a higher risk of mortality (HR = 4.31; 95% CI: 1.607-11.538; p = 0.004). Conclusions: Left ventricular hypertrophy is common in patients with severe AS prior to TAVI. The LVH pattern does not affect TAVI-related complications. In patients with severe AS referred for TAVI, CR seems to be the least favourable geometry of LVH, increasing the risk of 1-year all-cause death. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
11. Patient-prosthesis mismatch in patients treated with transcatheter aortic valve implantation - predictors, incidence and impact on clinical efficacy. A preliminary study.
- Author
-
Zbroński, Karol, Rymuza, Bartosz, Scisło, Piotr, Grodecki, Kajetan, Dobkowska, Paulina, Wawrzacz, Marek, Wilimski, Radosław, Słowikowska, Anna, Kochman, Janusz, Filipiak, Krzysztof J., Opolski, Grzegorz, and Huczek, Zenon
- Subjects
- *
AORTIC valve transplantation , *CHEMOEMBOLIZATION , *HEALTH outcome assessment , *AORTIC stenosis treatment , *BIOPROSTHESIS - Abstract
Introduction: Patient-prosthesis mismatch (PPM) is relatively frequent after surgical aortic valve replacement (SAVR) and negatively impacts prognosis. Aim: We sought to determine the frequency and clinical effects of PPM after transcatheter aortic valve implantation (TAVI). Material and methods: Overall, 238 patients who underwent TAVI were screened. Moderate PPM was defined as indexed effective orifice area (EOAi) between 0.65 and 0.85 cm2/m2, and severe PPM as < 0.65 cm2/m2. All-cause mortality and the Valve Academic Research Consortium 2 (VARC-2) defined composite of clinical efficacy at 1 year were the primary endpoints. Results: Finally, 201 patients were included (mean age: 79.6 ±7.4 years, 52% females). The femoral artery served as the delivery route in 79% and most of the prostheses were self-expanding (68%). Any PPM was present in 48 (24%) subjects, and only 7 (3.5%) had severe PPM. Body surface area (BSA) independently predicted any PPM (OR = 16.9, p < 0.001) whereas post-dilation tended to protect against PPM (OR = 0.46, p = 0.09). All-cause mortality was similar in patients with moderate or severe PPM as compared to those with no PPM (14.6% vs. 14.3% vs. 13.1%, respectively, log-rank p = 0.98). Neither moderate (OR = 1.6, 95% CI: 0.8-3.2, p = 0.16) nor severe PPM (OR = 1.67, 95% CI: 0.36-7.7, p = 0.51) had a significant impact on composite endpoint, or its elements, with the exception of transvalvular pressure gradient > 20 mm Hg. Conclusions: Severe PPM after TAVI is rare, can be predicted by larger BSA and does not seem to affect mid-term mortality or composite clinical outcome. Larger studies are needed to find different independent predictors of PPM and elucidate its impact in terms of device durability and long-term clinical efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.